Last updated July 18, 2026
Key finding
Time spent in target range increased from 51% to 52%.
This study evaluated a cloud-based platform for developing algorithms for type 1 diabetes using various artificial pancreas systems. It found slight improvements in glucose management metrics.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated a cloud-based platform for developing algorithms for type 1 diabetes using various artificial pancreas systems. It found slight improvements in glucose management metrics.
These findings are significant as they suggest that while new technologies like artificial pancreas systems may offer some benefits in managing blood glucose levels, the overall impact on hypoglycemia remains uncertain. This highlights the need for further research to fully understand the effectiveness of these interventions in real-world settings.
The study design was non-randomized, which may introduce bias. The sample size and demographic details were not specified. Effectiveness of interventions remains unclear due to lack of statistical significance.
Published in
Publication details and source links for this paper.
Mohamed RS, Remi R, Ahmad H, Othmar M. A cloud-based platform for developing and testing algorithms for type 1 diabetes. PLOS ONE. 2020;15(12):e0243139. doi:10.1371/journal.pone.0243139
Time spent at glucose levels in target range increased from 51% to 52%.
Mean glucose decreased from 7.9 to 7.8 mmol/L.
Time spent at glucose levels in target range increased from 62% to 63%.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Hybrid closed-loop system, Insulin therapy and Hypoglycemia events, Mean glucose from rtCGM, Time in range.
This study contributes evidence to
Primary intervention
Hybrid closed-loop system
Primary outcomes
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
6
Evidence pairs
486
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Hybrid closed-loop system → Hypoglycemia events
Hybrid closed-loop system → Hypoglycemia events
Hybrid closed-loop system → Mean glucose from rtCGM
Hybrid closed-loop system → Mean glucose from rtCGM
Insulin therapy → Mean glucose from rtCGM
Insulin therapy → Mean glucose from rtCGM
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Delivery Systems and CGM Time in Range, Insulin Therapies and CGM Time in Range.
This study contributes to the evidence on the following intervention-outcome relationships.
Devices & Technology
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring CGM Time in Range
Measures CGM Time in Range as a key outcome.
All studies on Insulin Delivery Systems
Contributes to Insulin Delivery Systems evidence base.
All studies on Insulin Therapies
Contributes to Insulin Therapies evidence base.
Jump to pre-filtered views in Evidence Explorer.
9 results
3 results
9 results
3 results
9 results
Generated from the study's connected evidence using Evidence Intelligence™.
Insulin Delivery Systems may improve CGM Time in Range.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Time in range
EvidenceScore™ Strong | EvidenceScore™ 81.2 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 18 supporting studies with consistent results and a positive effect signal.
Limitations
Insulin Therapies appears to improve CGM Time in Range.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Time in range
EvidenceScore™ Strong | EvidenceScore™ 77.4 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
Insulin Therapies may improve Hypoglycemia.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Hypoglycemia events
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 5 supporting studies with generally consistent results and a positive effect signal.
Limitations
Insulin Delivery Systems may improve Hypoglycemia.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Hypoglycemia events
EvidenceScore™ Strong | EvidenceScore™ 75.3 | weak positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 7 supporting studies with generally consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
